Previous close | 26.38 |
Open | 27.21 |
Bid | 26.31 x 300 |
Ask | 26.43 x 200 |
Day's range | 26.20 - 27.84 |
52-week range | 9.44 - 36.25 |
Volume | |
Avg. volume | 1,203,682 |
Market cap | 1.35B |
Beta (5Y monthly) | 2.86 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.58 |
Earnings date | 08 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 52.20 |
4D Molecular Therapeutics (FDMT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Preclinical data for 4D-175 for geographic atrophy to be presented in an oral presentation4D-150 PRISM randomized Phase 2 Dose Expansion Cohort (N=51) 24-week encore results to be presented in a poster EMERYVILLE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced presentations at the 2
On April 1, 2024, Chief Legal Officer Scott Bizily sold 8,153 shares of 4D Molecular Therapeutics Inc (NASDAQ:FDMT) according to a recent SEC Filing.